U.S. FDA Cites Added Risks In Astellas Overactive Bladder Drug
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma’s mirabegron drug for overactive bladders carries additional risk of increased blood pressure and heart rate and several hypersensitivity reactions that need to be weighed against potential benefit, said a U.S. FDA staff report.